Mechanistically, the effects of TSEC treatment in the endometrium and breast were proposed to be a result of the repression of ERα-mediated transcription and the promotion of ERα protein ubiquitination and degradation through FBXO45 in uterine tissue and breast cancer cells, but not in bone cells10, indicating that FBXO45 has a regulatory role in TSEC-mediated ERα degradation in endometrial and breast cells10. The gene discussed is FBXO45; the disease is breast cancer.